Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $43.15 USD
Change Today +0.26 / 0.61%
Volume 674.2K
NLNK On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 8:10 PM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

newlink genetics corp (NLNK) Snapshot

Open
$42.75
Previous Close
$42.89
Day High
$44.67
Day Low
$42.51
52 Week High
04/9/15 - $58.73
52 Week Low
10/13/14 - $17.32
Market Cap
1.2B
Average Volume 10 Days
487.0K
EPS TTM
$3.87
Shares Outstanding
28.6M
EX-Date
--
P/E TM
11.1x
Dividend
--
Dividend Yield
--
Current Stock Chart for NEWLINK GENETICS CORP (NLNK)

newlink genetics corp (NLNK) Details

NewLink Genetics Corporation, a biopharmaceutical company, focuses on discovering, developing, and commercializing immunotherapeutic products to enhance treatment options for patients with cancer. Its portfolio includes biologic product candidates based on its HyperAcute immunotherapy technology, which is designed to stimulate the human immune system; and small-molecule product candidates that are focused on breaking the immune system's tolerance to cancer by inhibiting the indoleamine-(2,3)-dioxygenase pathway and the tryptophan-(2.3)-dioxygenase pathway. The company’s lead product candidate, HyperAcute Pancreas immunotherapy, is being studied in Phase III clinical trials in surgically-resected pancreatic cancer patients, as well as in patients with advanced pancreatic cancer. It is also developing HyperAcute Lung immunotherapy for treating advanced non-small cell lung cancer; and HyperAcute Melanoma immunotherapy for treating advanced melanoma, as well as HyperAcute immunotherapies for renal, prostate, and breast cancers. In addition, the company is developing IDO pathway inhibitors comprising indoximod and NLG919 for metastatic breast cancer and metastatic prostate cancer; NLG2101 for patients with metastatic breast cancer; NLG2102 for treating refractory malignant brain tumors; NLG2103 for patients with advanced melanoma; and NLG2014 for patients with metastatic pancreatic cancer. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.

130 Employees
Last Reported Date: 03/16/15
Founded in 1999

newlink genetics corp (NLNK) Top Compensated Officers

Founder, Chairman, Chief Executive Officer an...
Total Annual Compensation: $573.2K
President, Chief Operations Officer and Chief...
Total Annual Compensation: $453.6K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $90.0K
Clinical & Regulatory Compliance Officer and ...
Total Annual Compensation: $312.2K
Vice President of Business Development
Total Annual Compensation: $262.5K
Compensation as of Fiscal Year 2014.

newlink genetics corp (NLNK) Key Developments

NewLink Genetics Corporation Provides Update on Phase 3 Pancreatic Cancer Trial

NewLink Genetics Corporation announced the continuation without any modification or sample size adjustment for its pivotal, Phase 3 IMmunotherapy for Pancreatic RESectable cancer Study, called "IMPRESS," of algenpantucel-L for patients with surgically resected pancreatic cancer following the second planned interim data analysis. IMPRESS is a multi-center, open-label clinical trial assessing the safety and efficacy of algenpantucel-L, NewLink Genetics' HyperAcute® Pancreatic Cancer immunotherapy candidate, conducted in more than 70 leading cancer centers. With 722 patients enrolled, IMPRESS is the large trial to be completed in the United States for patients with resected pancreatic cancer. Algenpantucel-L has received fast-track status and orphan drug designation from the U.S. Food and Drug Administration (FDA). NewLink Genetics and the FDA reached agreement in January 2010 on a Special Protocol Assessment (SPA) on the trial design, clinical endpoints and statistical analyses plan for IMPRESS to be used in support of a Biologic License Application (BLA). After careful consideration, including a series of communications with the FDA regarding the statistical analysis plan, the Company decided to retain the benefit of the SPA and not to change the statistical analysis plan as defined in the original protocol. For the second interim analysis, the independent data safety monitoring committee (DSMC) reviewed available patient data with the originally planned log-rank analysis and sample size recalculation, in all respects consistent with the SPA. No other statistical methods were used. The DSMC recommended the study proceed without any modifications, including sample size adjustment, to final analysis. Therefore the Company believes the trial remains powered to determine efficacy upon the occurrence of 444 events.

NewLink Genetics Corporation Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Financial Guidance for the Year 2015

NewLink Genetics Corporation reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenues of USD 39.195 million compared to USD 0.334 million a year ago. Income from operations was USD 12.848 million compared to loss from operations of USD 9.304 million a year ago. Income before income taxes was USD 12.859 million compared to loss before income taxes of USD 9.236 million a year ago. Net income was USD 11.190 million compared to net loss of USD 9.236 million a year ago. Diluted earnings per share was USD 0.35 compared to diluted loss per share of USD 0.33 a year ago. The company expects to end the year on December 31, 2015, with approximately USD 160 million in cash, cash equivalents and certificates of deposit. This guidance recognizes that an early halt in the IMPRESS trial for effectiveness would require the need to accelerate organizational development and spending levels.

NewLink Genetics Corporation Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-14-2015 12:40 PM

NewLink Genetics Corporation Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-14-2015 12:40 PM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NLNK:US $43.15 USD +0.26

NLNK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NLNK.
View Industry Companies
 

Industry Analysis

NLNK

Industry Average

Valuation NLNK Industry Range
Price/Earnings 11.2x
Price/Sales 5.7x
Price/Book 5.3x
Price/Cash Flow 9.9x
TEV/Sales 4.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEWLINK GENETICS CORP, please visit www.newlinkgenetics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.